Current Studies

MATISSE Maternal Vaccine Study

Find out more about this study

Please fill out the form below and we will be in touch shortly.

Participants needed: Women between 18-49

Participants needed: Women aged 18-49

View Poster: Pass on what’s important (.pdf)

What is RSV?

Respiratory syncytial (sin-SISH-uhl) virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants. RSV is a common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age.

Like the flu, RSV has season patterns, but unlike the flu there are no currently approved vaccines for the virus.

Purpose

The MATISSE maternal vaccine study wants to find out if giving expecting mothers an investigational vaccine or respiratory syncytial virus (RSV) is safe and could help protect their babies from RSV after they are born.

Eligibility

You might qualify for this research if you are:

  • Between 18 and 49 years old
  • Healthy and expecting a single healthy baby
  • Between 24 to 36 weeks pregnant when you receive the study vaccine
  • Not planning on having your baby at home
  • Willing and able to attend study visits and follow instructions from your study team

You need to meet other requirements to participate and your study team will talk you through these requirements during a screening visit.

Your Involvement

You will have four planned study visits over the course of about 10 months after you receive the vaccine. Your baby will have six planned study visits during the first 24 months of their life. Your baby may have extra study visits if they get sick. Some of these checks may be done over the phone.

NOTE: We ask that you review the information and consent form before volunteering for this study. After review, please contact Angi Perreault. The information and consent form will be reviewed with you during your first site visit before signing.

Contact Angi Perreault

Phone 902-470-3741

Email angela.perreault@iwk.nshealth.ca

Find out more about this study

Please fill out the form below and we will be in touch shortly.